Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Administration of P1101 and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
NCT04638439Phase 1Completed
- Sponsor
- PharmaEssentia
- Start
- Aug 2022
- Primary completion
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ropeginterferon alfa-2b and nivolumab in Chronic Hepatitis B (CHB) and chronic hepatitis D, sponsored by PharmaEssentia. Primary endpoints: Adverse Events and Serious Adverse Events and Clinically significant abnormalities. Started Aug 2022; status: completed.
02
Drugs
ropeginterferon alfa-2bnivolumab
03
Conditions
Chronic Hepatitis B (CHB)chronic hepatitis D
Beyond the preview
Go deeper on NCT04638439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04638439.